Immunic AG
Nasdaq IMUX · New York, United States
Works in GI & liver · Immunology · Infectious disease · Neurology · Respiratory
Immunic AG is a clinical trial sponsor based in New York, United States, listed as Nasdaq IMUX. It has 3 active clinical trials with 2,431 planned participants, across 5 therapeutic areas. Since 2021 it has completed 1 trial and stopped 2 early.
Trial track record · since 2021
Financials · Nasdaq IMUX
Fundraising
Pipeline · 3 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Immunic AG
Immunic AG is lead sponsor of 3 active clinical trials on ClinicalTrials.gov, with 2,431 planned participants, in GI & liver, Immunology, Infectious disease, Neurology and other areas. Since 2021 it has completed 1 trial and stopped 2 early.
Immunic AG is based in New York, United States and is listed as Nasdaq IMUX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Immunic AG; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-01.
Approve Suite is not affiliated with Immunic AG.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.